1. Home
  2. CRDF vs MKTW Comparison

CRDF vs MKTW Comparison

Compare CRDF & MKTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

SELL

Current Price

$0.87

Market Cap

67.1M

Sector

Health Care

ML Signal

SELL

Logo MarketWise Inc.

MKTW

MarketWise Inc.

SELL

Current Price

$20.68

Market Cap

55.9M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
CRDF
MKTW
Founded
1999
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
67.1M
55.9M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
CRDF
MKTW
Price
$0.87
$20.68
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$5.14
★ $24.16
AVG Volume (30 Days)
★ 1.0M
14.5K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
★ 8.72%
EPS Growth
27.37
★ 1183.33
EPS
N/A
★ 0.12
Revenue
$365,993.00
★ $512,403,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$6.59
P/E Ratio
★ N/A
$168.29
Revenue Growth
★ 49.61
N/A
52 Week Low
$0.71
$13.49
52 Week High
$3.31
$23.00

Technical Indicators

Market Signals
Indicator
CRDF
MKTW
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
CRDF
MKTW

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.

Share on Social Networks: